2015 ANTIMICROBIAL OVERVIEW - myCMEmedia.mycme.com/documents/198/2016_antimicrobial_overview_493… · Antimicrobial Overview June 2015 Rutgers, The State University of New Jersey

1

Antimicrobial Overview June 2015

Rutgers, The State University of New Jersey

Laureen A. Klein, Pharm.D.

PANCE/PANRE Review Course

General Principles

• Narrowest spectrum possible to avoid resistance

• Wider spectrum (including multiple agents) – neutropenic fever, polymicrobial infection, synergism (two agents with different mechanisms of action), tuberculosis

• Ensure compliance


Aerobic Gram-Positive Bacteria

• Streptococcus

• Staphylococcus

• Enterococcus

• Cornybacterium

• ListeriaListeria

2


Aerobic Gram-Negative Bacteria

• Enterobacteriaceae (E. coli, Klebsiella, Enterobacter, Citrobacter, Proteus, Serratia, Salmonella, Shigella, Morganella, Providencia)

• Pseudomonas• Helicobacter• Haemophilus• Haemophilus• Legionella• Moraxella• Neisseria


Anaerobic Bacteria

• Gram-Positive• Peptococcus

• Peptostreptococcus

• Clostridia

• Propionibacterium acnes

• Gram-Negative• Bacteroides

• Fusobacterium

• Propionibacterium acnes


Atypicals

• Chlamydia

• Chlamydophila

• Rickettsiae

• Mycoplasma

• Spirochetes (Syphilis, Lyme disease)Spirochetes (Syphilis, Lyme disease)

• Mycobacterium (tuberculosis, mycobacterium avium complex [MAC])

3


Mechanisms of Action (MOA)

• Cell wall synthesis inhibitors – beta-lactams (penicillins, cephalosporins, monobactam, carbapenems), vancomycin, lipoglycopeptides, fosfomycin, bacitracin

• Protein synthesis inhibitors – macrolides, ketolides, aminoglycosides tetracyclines metronidazoleaminoglycosides, tetracyclines, metronidazole, dalfopristin/quinupristin, oxazolidinones (linezolid, tedizolid), clindamycin

• Inhibition of enzymes – rifampin (RNA polymerase), fluoroquinolones (topoisomerase), sulfamethoxazole/ trimethoprim (folic acid)


Penicillins

• MOA: beta-lactams; bind to penicillin binding protein to inhibit cell wall synthesis

• Spectrum: gram-positives (S. pneumoniae & Staphylococcal resistance), gram-negatives, anaerobes

• Most eliminated renally

• Resistance: beta-lactamase, altered penicillin binding protein, altered penetration

• AEs: hypersensitivity, GI, hematological, seizures, interstitial nephritis


Natural Penicillins(Pen G, Pen VK [PO], Procaine [IM], Benzathine IM])

• Spectrum: Treponema pallidum, Streptococcal species (pyogenes, pneumoniae [resistance]), Enterococcus (combined with aminoglycoside), Neisseria meningitidis, Borrelia burgdorferi, anaerobes above diaphragm

• Indications: syphilis and strep respiratory tract infections including S. pneumoniae and S. pyogenes

4


Antistaphylococcal Penicillins(dicloxacillin, nafcillin, oxacillin, methicillin)

• Spectrum: staphylococcal and streptococcal infections only

• Effective for penicillinase producing organisms• If methicillin resistantresistant to all beta lactams• If methicillin resistant resistant to all beta-lactams

except ceftaroline• Indications: sensitive staphylococcal infections, generally

skin infections• Nafcillin has hepatobiliary elimination


Amino Penicillins (ampicillin, amoxicillin)

• Spectrum: Streptococcal species, Enterococci, Listeria, Enterobacteriaceae, Borrelia burgdorferi, Helicobacter pylori

• Indications: respiratory tract infections, Lyme, GI ulcers – H. pylori, endocarditis prophylaxis

• Mononucleosis – maculopapular rash – no urticaria


Extended-Spectrum Penicillins(piperacillin, ticarcillin)

• Spectrum: extended gram-negative coverage including Pseudomonas aeruginosa

• Indications: infections in hospitalized patients

• Intravenous only – inpatient treatment y p

5


Penicillin + Beta-lactamase Inhibitors

• Agents: oral - amoxicillin/clavulanate (Augmentin), IV -ampicillin/sulbactam (Unasyn), piperacillin/tazobactam (Zosyn), ticarcillin/clavulanate (Timentin)

• Spectrum: extends spectrum to beta-lactamase producing organisms (eg, S. aureus, Haemophilus, Neisseria, Moraxella, Bacteroides, Enterobacteriaceae))

• Indications: Augmentin - respiratory tract infections, animal bites, skin infections and Others - serious infections

• AE: clavulanatediarrhea


Cephalosporins

• MOA: beta-lactams, inhibit cell wall synthesis

• Spectrum: gram-positive, gram-negative

• 1st, 2nd, 3rd, 4th, 5th generation

• Mostly renal elimination

• AEs: hypersensitivity (cross-sensitivity with penicillin), GI,AEs: hypersensitivity (cross sensitivity with penicillin), GI, hematologic, serum sickness

• Drug interactions: some have decreased absorption with decreased GI acidity


First Generation Cephalosporins

• Oral: cephalexin (Keflex), cephradine (Velosef), cefadroxil (Duricef)

• Parenteral: cefazolin (Ancef, Kefzol)• Spectrum: gram-positives (staph and strep), limited gram-

negatives, oral anaerobes• Indications: alternative for staphylococcal (MSSA) and• Indications: alternative for staphylococcal (MSSA) and

streptococcal infections, surgical prophylaxis

6


Second Generation Cephalosporins

• Oral: cefaclor (Ceclor), cefprozil (Cefzil), cefuroxime (Ceftin)

• Parenteral: cefuroxime (Zinacef), cefoxitin (Mefoxin), cefotetan (Cefotan)

• Spectrum: MSSA, S pneumoniae, S pyogenes, H influenzae, Proteus, Moraxella catarrhalis, Borrelia burgorferi – less gram-positive and more gram-negative than first generation

– anaerobes – some cover B. fragilus (cefoxitin, cefotetan)

• Indications: respiratory tract infections, UTIs, Lyme, skin infections, surgical prophylaxis


Second Generation Cephalosporins

• Cefaclor – serum sickness

• Methylthiotetrazole (MTT) side chain – cefotetan -hypothrombinaemia, alcohol intolerance (flushing, tachycardia, N/V, hypotension, dyspnea)


Third Generation Cephalosporins

• Oral: cefixime (Suprax), cefpodoxime (Vantin), cefdinir (Omnicef), ceftibuten (Cedax), cefditoren (Spectracef)

• Parenteral: ceftriaxone – IV and IM (Rocephin), ceftazidime (Fortaz or Tazicef), cefotaxime (Claforan)

• Spectrum: less gram-positive and more gram-negative (H influenzae, E coli, Moraxella catarrhalis, Proteus, Klebsiella) than first and second generation, ceftriaxone – Borrelia burgdorferi– P. aeruginosa: ceftazidime

• Indications: respiratory tract infections, UTIs, meningitis (ceftriaxone, cefotaxime), gonorrhea (ceftriaxone + azithromycin or doxycycline)

• Ceftriaxone has hepatobiliary elimination

7


Fourth/Fifth Generation Cephalosporins

• Cefepime (Maxepime) – parenteral

– gram-positive and gram-negative activity

– increased stability to beta-lactamases and activity against Pseudomonas aeruginosa

• Ceftaroline (Teflaro)- parenteral

– gram-positive and gram-negative activity

– activity against MRSA and resistant S. pneumoniae

– no activity against Pseudomonas aeruginosa or extended spectrum beta-lactamases


Cephalosporin + Beta-lactamase Inhibitors

• Agents: ceftazidime and avibactam (Avycaz), ceftolozane + tazobactam (Zerbaxa)

• Spectrum = ceftazidime gram-negative coverage + coverage for beta-lactamase producing organisms – includes Pseudomonas aeruginosa

• Indications: Complicated intra-abdominal infections and urinary tract infections

• AEs: GI effects


Third Generation Cephalosporins

• Oral: cefixime (Suprax), cefpodoxime (Vantin), cefdinir (Omnicef), ceftibuten (Cedax), cefditoren (Spectracef)

• Parenteral: ceftriaxone – IV and IM (Rocephin), ceftazidime (Fortaz or Tazicef), cefotaxime (Claforan)

• Spectrum: less gram-positive and more gram-negative (H influenzae, E coli, Moraxella catarrhalis, Proteus, Klebsiella) than first and second generation, ceftriaxone – Borrelia burgdorferi– P. aeruginosa: ceftazidime

• Indications: respiratory tract infections, UTIs, meningitis (ceftriaxone, cefotaxime), gonorrhea (ceftriaxone + azithromycin or doxycycline)

• Ceftriaxone has hepatobiliary elimination

8


Monobactam

• Aztreonam (Azactam)– parenteral

• MOA: inhibits cell wall synthesis

• Spectrum: aerobic gram-negative only including Pseudomonas aeruginosa

• Indications: alternative agentg

• AEs: limited risk of cross-reactivity, GI


Carbapenems

• Agents: imipenem (Primaxin), meropenem (Merrem), ertapenem (Invanz), doripenem (Doribax) – all parenteral

• MOA: inhibits cell wall synthesis• Spectrum: very broad, includes gram-positives, gram-

negatives, anaerobes– Ertapenem has narrower spectrum – no Pseudomonas– Ertapenem has narrower spectrum – no Pseudomonas– Coverage includes extended spectrum beta-lactamase (ESBL)

producing organisms

• AEs: hypersensitivity (cross-reactivity with penicillins), GI, seizures, hypotension


Fluoroquinolones

• norfloxacin (Noroxin)

• ciprofloxacin (Cipro)

• ofloxacin (Floxin)

• levofloxacin (Levaquin)

• gemifloxacin (Factive)gemifloxacin (Factive)

• moxifloxacin (Avelox)

*Oral and parenteral agents

*Renal and hepatic elimination

9


Fluoroquinolones

• MOA: bind to and inhibit topoisomerases II & IV

• Good tissue penetration

• Spectrum: gram-positives (issues of resistance), gram-negatives (cipro & levo - P. aeruginosa, gonorrhea resistance), atypicals (chlamydia, mycoplasma), some have ), yp ( y , y p ),anaerobic coverage – moxifloxacin

• Resistance: modified DNA gyrase

• Concentration-dependent efficacy and post-antibiotic effect

• Indications: respiratory tract infections, skin infections (newer agents), UTIs, anthrax, GI infections (Salmonella, Shigella, Traveler’s diarrhea)


Fluoroquinolones - Adverse Events

• GI

• CNS – headache, peripheral neuropathy

• Cartilage toxicity (no peds)

• Tendinitis and tendon rupture – black box warning

Ph t iti it• Photosensitivity

• QT prolongation

• Hypo/hyperglycemia

• Rash

• Exacerbation of myasthenia gravis

• Increased liver function tests


Fluoroquinolones - Drug Interactions

• Divalent/trivalent cations - chelation

• Drugs affecting QT interval

• Drugs affecting blood glucose

• Theophylline

• WarfarinWarfarin

10


Macrolides• Agents: erythromycin, clarithromycin (Biaxin), azithromycin

(Zithromax)

• oral/parenteral

• MOA: inhibit protein synthesis

• Spectrum: – gram-positives, including Staphylococcus aureus, S pneumonia, g p , g p y , p ,

and S pyogenes, C&E>A, some staphylococcal and pneumococcal resistance

– some gram-negatives including H. pylori, H influenzae, Moraxella catarrhalis, Legionella, A>C>E, none have activity against Pseudomonas or Enterobacteriaceae)

– atypicals (mycoplasma, Chlamydophila pneumonia, Chlamydia trachomatis, Treponema pallidum)

• Indications: respiratory tract infections (CAP), GI ulcers (clarithro), MAC (azithro & clarithro), chlamydia STDs, skin infections


Macrolides

• Azithromycin half-life = 2-4 days

• Hepatic elimination

• AEs: GI (stimulates GI motility), ototoxicity, prolong QT, cholestatic jaundice (erythro), metallic taste (clarithromycin), phlebitis (erythro)

• Drug Interactions: inhibit cytochrome P450


Ketolides (telithromycin - Ketek)

• MOA: protein synthesis inhibitor• Spectrum: gram-positive, gram-negatives, atypicals, some

anaerobes• AEs: hepatic dysfunction (contraindicated in peds),

contraindicated in patients with myastenia gravis, GI, vision problems, QT prolongationproblems, QT prolongation

• Drug Interactions: inhibits cytochrome P450

11


Tetracyclines(tetracycline, doxycycline, minocycline)

• MOA: protein synthesis inhibitors• Spectrum: Propionibacterium acnes, H. pylori, Rickettsia,

Chlamydia, Mycoplasma, Borrelia burfdorferi, Treponema pallidum, community-acquired MRSA, Streptococcus pneumoniae (resistance issues)pneumoniae (resistance issues)

• Indications: acne, respiratory tract infections (including community-acquired pneumonia), Lyme, GI ulcers (tetracycline), Rocky Mountain Spotted Fever, chlamydia, community-acquired MRSA

• Mostly hepatic elimination


Tetracyclines

• AEs: photosensitivity, deposition in teeth and bones (no peds & pregnancy), GI, vestibular reactions (minocycline), hepatotoxicity

• Drug Interactions: chelation with divalent and trivalent cations, oral contraceptives, warfarin


Glycylcyclines (tigecycline-Tygacil)

• Parenteral

• MOA: protein synthesis inhibitor

• Spectrum: gram-positive (including MRSA), gram-negatives, anaerobes, atypicals

• Indications: alternative agentg

• AEs: GI, photosensitivity, tooth discoloration (no peds or pregnancy)

12


Aminoglycosides(gentamicin, tobramycin, amikacin)

• Parenteral

• MOA: protein synthesis inhibitors

• Spectrum: aerobic gram-positives and gram-negatives (P. aeruginosa)

• Concentration dependent efficacy and post antibiotic effect• Concentration dependent efficacy and post-antibiotic effect

• Indications: generally gram-negative infections in hospital

• Synergy with beta-lactams

• AEs: nephrotoxicity, ototoxicity, neuromuscular blockade (myasthenia gravis)

• Renally excreted

• Monitor serum concentrations


Sulfonamides

• MOA: inhibit folic acid synthesis

• Spectrum: gram-positive (Staphylococcus aureus, Streptococcus pneumoniae) and gram-negative (H. influenzae, Moraxella catarrhalis, E coli, Proteus) Pneumocystic jiroveci

• Indications: trimethoprim/sulfamethoxazole (TMP/SMX [Bactrim, Septra]): respiratory tract infections, UTIs, PCP, community-acquired MRSA

• AEs: GI, hypersensitivity (includes Stevens Johnson Syndrome), bone marrow suppression, photosensitivity

• DIs: oral contraceptives, warfarin, sulfonylureas


Metronidazole (Flagyl)Tinidazole (Tindamax)

• Oral/parenteral

• Spectrum: anaerobes (Bacteroides, C. difficile) and parasites (Trichomonas, Giardia, Entamoeba), H. pylori

I di ti GI i f ti l i l i f ti• Indications: GI infections, gynecological infections, trichomoniasis


• AEs: metallic taste, GI, CNS, dark urine

• Drug Interactions: warfarin

• Alcohol intolerance (flushing, tachycardia, N/V, hypotension, dyspnea)

13


Fidaxomicin (Dificid)

• Oral

• MOA: inhibits protein synthesis

• Spectrum: Clostridium difficile

• Not systemically absorbed

• AEs: nausea, vomitingAEs: nausea, vomiting


Clindamycin

• MOA: inhibit protein synthesis

• Spectrum: gram positive and anaerobes

• MRSA – community-acquired


• Alternative agent in penicillin allergic patientsAlternative agent in penicillin allergic patients

• AEs: GI – pseudomembranous colitis


Rifampin

• MOA: inhibits RNA synthesis

• Indications: TB, eradication of nasal carriage of H. flu, Meninogococcus, Staphylococcus, additional agent for resistant infections


• AEs: orange-red body fluids, hepatotoxicity, GI, flu-like symptoms

• Drug Interactions: induces cytochrome P450

14


Methicillin-Resistant Staphylococcus aureus (MRSA)

• Vancomycin

• Linezolid (Zyvox) and Tedizolid (Sivextro) - oral

• Dalfprostin/quinupristin (Synercid)

• Daptomycin (Cubicin)

• Lipoglycopeptides: telavancin (Vibativ), oritavancin (Orbactiv), dalbavancin (Dalvance)

• Others: tigecycline, ceftaroline

• Community: clindamycin, tetracycline , trimethoprim/sulfamethoxazole- oral


Vancomycin

• Inhibits cell wall synthesis – binds to peptidoglycan precursor and prevents cross-linking of peptidoglycan strands (different than beta-lactams)

• Parenteral: MRSA – drug of choice, also other staph and strep infections and Enterococcus faecalis

• Oral – not absorbed - C. difficile treatmentOral not absorbed C. difficile treatment• Renal excretion• AEs: red man’s syndrome, thrombophlebitis, nephrotoxicity,

ototoxicity• Monitor serum concentrations – trough concentrations –

10-20 mg/L


Oxazolidinones

• Linezolid (Zyvox) and Tedizolid (Sivextro)• Oral/Parenteral• Inhibit protein synthesis• MRSA, enterococci, streptococci• AEs: myelosuppression (monitor CBC), GI, headache,

thneuropathy• Drug interactions:

– Linezolid inhibits monoamine oxidase (MAO) – avoid tyramine (aged cheese, sausage, beer), selective seretonin reuptake inhibitors (SSRIs), pseudoephedrine, tricyclic antidepressants, bupropion, sumatriptin, beta2 agonists, sympathomimetics, tryptophan, ginseng, dopamine, dobutamine, sibutramine

15


Lipoglycopeptides• Telavancin (Vibativ), Oritavancin (Orbactiv), Dalbavancin

(Dalvance)

• All parenteral only

• Vancomycin derivatives

• Spectrum: MRSA, streptococci, enterococci

• Dalbavancin 2 doses one week apart• Dalbavancin – 2 doses one week apart

• Oritavancin – single dose

• AEs: nausea, vomiting, headache, diarrhea, infusion reactions– taste disturbances, QT prolongation, foamy urine, and

nephrotoxicity with telavancin

• DIs - CYP450 - oritavancin - warfarin (CYP2D6)

• Coagulation test interference: telavancin and oritavancin


Methicillin-Resistant Staphylococcus aureus (MRSA)

• Dalfprostin/quinupristin (Synercid) – IV

– AEs: arthralgias, rash, hyperbilirubinemia, N/V, headache

– Inhibits CYP450

• Daptomycin (Cubicin) – IV

– AEs: increased CPK (monitor weekly), GI, CNS


UTIs

• Nitrofurantoin

• Fosfomycin

• Methenamine

• All have some GI effects

• Generally recommended treatment for uncomplicated UTI is trimethoprim/sulfamethoxazole

16


Herpes Viruses

• acyclovir (Zovirax), famciclovir (Famvir), valacyclovir (Valtrex)• Herpes simplex (first episode, treatment/suppression of

recurrences, decrease transmission)• Herpes zoster – varicella (speed healing, decrease pain &

neuralgia)• Severe infectionacyclovir• Severe infectionacyclovir• AEs: GI, headache


Influenza• Zanamivir (Relenza – inhaled), oseltamivir (Tamiflu - oral),

peramivir (Rapivab - IV)

– Influenza A and B treatment (w/in 2 d) and prevention

– Influenza A resistance to oseltamivir

– Zanamivir – bronchospasm

– Oseltamivir – nausea vomiting HAOseltamivir nausea, vomiting, HA

– Peramivir – diarrhea

• Amantadine and rimantadine

– Influenza A treatment and prevention (due to resistance issues not currently recommended)

– AEs: GI, CNS (less with rimantadine)


Cytomegalovirus (CMV)

• Ganciclovir (Cytovene), valganciclovir (PO, Valcyte) – bone marrow suppression

• Foscarnet (Foscavir) –nephrotoxicity, electrolyte disorders, bone marrow suppression

• Cidofovir (Vistide) – nephrotoxicity, neutropenia

• Fomivirsen (Vitravene) – ocular toxicity

17


Hepatitis B

• Preferred Agents:

– Nucleos(t)ide analogues: (entecavir [Baraclude], tenofovir [Viread])

– Interferon, pegylated interferon

• Nonpreferred treatments: lamivudine, adefovir, telbivudine, emtricitabine

• All treatment decrease HBV DNA levels and have been associated with HBeAG loss/seroconversion, decreases in ALT, and improvements in liver histology


Hepatitis B

• Nucleos(t)ide analogues (oral)– Greater and faster decline in HBV DNA levels than with

interferon– Long-term treatment required– Resistance issues (low with tenofovir and entecavir)– Minimal side effects – HA, GI

• Interferon (SC)– 16 – 48 weeks treatment duration– AEs: many, including flu-like symptoms, bone marrow

suppression, and psychiatric symptoms


Hepatitis C – Initial Treatment - Directly acting antivirals

• Genotype 1a– Ledipasvir/Sofosobuvir (Harvoni)

– Ombitasvir/Paritaprevir/Ritonavir/ Dasabuvir (Viekira Pak) + Ribavirin

– Simeprevir (Olysio) + Sofosobuvir (Sovlaldi) +/- ribavirin

• Genotype 1b– Ledipasvir/Sofosobuvir (Harvoni)

– Simeprevir (Olysio) + Sofosobuvir (Sovaladi)

– Ombitasvir/Paritaprevir/Ritonavir/ Dasabuvir (Viekira Pak) +/-ribavirin

• Genotype 2– Sofosobuvir (Sovaldi) + ribavirin

• Genotype 3– Sofosobuvir (Sovaldi) + ribavirin

http://www.hcvguidelines.org

18


Hepatitis C – Adverse events• Sofosobuvir (Sovaldi): fatigue, headache, nausea

• Simeprevir (Olysio) + sofosobuvir (Sovaldi): fatigue, headache, nausea, insomnia, pruritus, rash, photosensitivity

• Ombitasvir/paritaprevir/ritonavir/ dasabuvir (Viekira Pak): skin reactions, insomnia, asthenia, irritability, fatigue, s eac o s, so a, as e a, ab y, a gue,pruritus, nausea, increased bilirubin and LFTs, anemia (contraindications due to drug interactions)

• Ledipasvir/sofosobuvir (Harvoni): fatigue, headache, nausea, diarrhea, insomnia

• Ribavirin: anemia, teratogen

• Multiple drug interactions (CYP450, acid suppressiondecreases absorption)


Antifungals

• Polyenes: amphotericin – wide spectrum• Azoles: ketoconazole (Nizoral), fluconazole (Diflucan),

itraconazole (Sporonax), voriconazole (Vfend), posaconazole (Noxafil) – spectrum varies from one agent to the other

• Terbinafine (Lamisil) dermatophyte infections• Terbinafine (Lamisil) – dermatophyte infections• Flucytosine – only as part of combination therapy• Echinocandins: caspofungin (Cancidas), micafungin

(Mycamine), anidulafungin (Eraxis) – candida and aspergillosis


Antifungals – Adverse Events

• Amphotericin: nephrotoxicity, electrolyte disorders, anemia, flu-like symptoms

• Azoles: hepatotoxicity, QT prolongation, ketoconazole-decreased cortisol & testosterone, voriconazole-vision

• Terbinafine: hepatotoxicityTerbinafine: hepatotoxicity• Echinocandins: histamine-mediated reactions,

hepatotoxicity, GI, HA, fever, phlebitis, hypokalemia, bone marrow suppression

• Griseofluvin: GI, HA, hepatotoxicity• Flucytosine: bone marrow suppression, GI, hepatitis

19


Antifungals – Important Drug Interactions

• Azoles inhibit cytochrome P450

• Ketoconazole & itraconazole require GI acidity for absorption

• Rifampin increases clearance of azoles


Bugs and Drugs

• Methicillin sensitive Staphylococcus aureus (MSSA): penicillinase-resistant penicillin (eg, nafcillin, dicloxacillin), first-generation cephalosporin

• MRSA serious: vancomycin

• MRSA outpatient: clindamycin, tetracycline, linezolid p y , y ,

• Streptococcus pyogenes: penicillin or amoxicillin, first generation cephalosporin

– penicillin allergic – clindamycin or macrolide

• Streptococcus pneumoniae – outpatient infections –penicillin V, amoxicillin, cephalosporins, macrolides


Bugs and Drugs

• Haemophilus influenzae and Moraxella catarrhalis: second or third generation cephalosporin, amoxicillin + clavulanic acid

• Pseudomonas aeruginosa –

– Oral: ciprofloxacin and levofloxacinp

– Intravenous: ticarcillin, piperacillin, ceftazidime, cefepime, aztreonam, aminoglycosides, carbapenems (except ertapenem), ceftolozane + tazobactam

20


Bugs and Drugs

• Neisseria gonorrhoeae: ceftriaxone + azithromycin or doxycycline

• Neisseria meningitis: ceftriaxone, cefotaxime

• Clostridium difficile: metronidazole, vancomycin, fidaxomicin

• Chlamydia: azithromycin and doxycycliney y y y

• Mycoplasma pneumoniae: macrolide or tetracycline

• Borrelia burgdorferia (Lyme): doxycycline, amoxicillin, cefuroxime axetil

• Treponema pallidum (Syphilis): penicillin G, benzathine penicillin

• Helicobacter pylori: proton pump inhibitor + clarithromycin + amoxicillin or metronidazole


Antibiotic Adverse Events Highlights

• Photosensitivity – SMP/TMX, tetracyclines, fluoroquinolones, tigecycline, hepatitis C treatments

• Rash – multiple agents (fluoroquinolones*)

• QT prolongation – macrolides, fluoroquinolones, telithromycin lipoglycopeptidestelithromycin, lipoglycopeptides

• Infusion reactions – vancomycin, lipoglycopeptides

• Nephrotoxicity – vancomycin, aminoglycocides, amphotericin, penicillins, tetracycline (outdated), foscarnet, cidofovir

• Hepatotoxicity – antifungals

• Ototoxicity – aminoglycosides, minocycline (vestibular), amphotericin


Adverse Events Highlights

• Seizures – penicillin, fluoroquinolones, carbapenems

• Mononucleosis – erythematous rash – amoxicillin

• Bone marrow suppression –sulfamethoxazole/trimethoprim, linezolid, ganciclovir, foscarnet interferon flucytosinefoscarnet, interferon, flucytosine

• Clostridium difficile infections – all (clindamycin*)

• GI – multiple agents (clavulanate*)

21


Adverse Events Highlights

• Taste disturbance – clarithromycin, metronidazole, tinidazole, telavancin

• Tendonitis – fluoroquinolones

• Orange-red fluids – rifampin

• Discolored teeth and bone deposits - tetracyclinesp y

• Contraindicated in pediatrics and pregnant women-tetracyclines, fluoroquinolones, tigecycline, telithromycin

• Contraindicated in neonates: sulfa agents

• Teratogen - ribavirin


Drug Interactions Highlights

• Macrolides, dalfopristin/quinupristin, telithromycin , azole antifungals – inhibit cytochrome P450

• Rifampin – induces cytochrome P450

• Fluoroquinolones and tetracyclines – chelated by divalent d t i l t tiand trivalent cations

• Linezolid – monoamine oxidase inhibitors

• Alcohol – disulfuram reaction (headache, tachycardia, flushing, GI) - metronidazole, cefotetan

• Hepatitis C and HIV treatments – multiple cytochrome P450 interactions

• Decrease in GI acidity decreases absorption of some azoles and some antivirals (hepatitis C and HIV)


Thank you!Thank you!

2015 ANTIMICROBIAL OVERVIEW - myCMEmedia.mycme.com/documents/198/2016_antimicrobial_overview_493… · Antimicrobial Overview June 2015 Rutgers, The State University of New Jersey

Documents